UBX - Unity Biotechnology cuts stock sales agreement in half to $25M
- Unity Biotechnology ( NASDAQ: UBX ) has halved a stock sales agreement to $25M from $50M , according to a Friday SEC filing.
- The sales agreement is through Cowen.
- Unity noted that it already sold $8.9M worth of shares under the agreement.
- On Thursday, the company priced shares of another offering of its common stock and accompanying warrants at a combined public offering price of $0.70/share and accompanying warrant . The gross proceeds are expected to be $45M.
For further details see:
Unity Biotechnology cuts stock sales agreement in half to $25M